SlidesetViral Hepatitis and Liver DiseaseStopping Nucleos(t)ide Analogues: Clinical outcomes of HBs Loss, retreatment and flares- Pietro Lampertico, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseImmunological response after stopping Nucs- Andre BoonstraView Slideset
SlidesetViral Hepatitis and Liver DiseaseVirological biomarkers in patients stopping Nucs- Florian van Bommel, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseReview of the FDA/EMA HBV Endpoints Meeting- Fabien Zoulim, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseAre ALT Flares Associated with Improved Virological Clearance- Harry Janssen, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHigh Resolution of Exhausted T cells Ex Vivo in Chronic HBV Infection- Robert ThimmeView Slideset
SlidesetViral Hepatitis and Liver DiseaseRestoration of B cell Antibody Production in Chronic HBV patients- Mala Maini, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseAre HBcrAg, HBV RNA and anti-HBc Viable Biomarkers- Florian van Bommel, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseUsing FNAB to Investigate Intrahepatic Immunology- Adam Gehring, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseElimination of Residual HBV Replication and Prevention of cccDNA Generation with the Combination of NrtI and Core Inhibitor- Richard ColonnoView Slideset
SlidesetViral Hepatitis and Liver DiseasesIRNA based therapy for Chronic Hepatitis B Treatment- Michael BiermerView Slideset
SlidesetViral Hepatitis and Liver DiseaseNAP's latest update in HBV and HDV- Andrew VaillantView Slideset
SlidesetViral Hepatitis and Liver DiseaseStudy Design with New Combinations- Marion Peters, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHypothesized Synergies in new cobmination treatment beyond nucs- Jordan Feld, MD, MPHView Slideset
